From the publisher feed
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
Read the original at STAT ↗Opens the original publisher page. Access, copyright and subscriptions are controlled by the publisher.
A useful next step
- Read the short publisher description here.
- Open the full report directly at the publisher.
- Compare this topic with other sources when useful.